4.4 Article

Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative study

Journal

TRIALS
Volume 21, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13063-020-04234-0

Keywords

Digital tool; Participant recruitment; Participant retention; Qualitative; Survey; Clinical trials unit

Funding

  1. NIHR Clinical Trials Unit Support Funding grant

Ask authors/readers for more resources

Background Recruitment and retention of participants in randomised controlled trials (RCTs) is a key determinant of success but is challenging. Trialists and UK Clinical Research Collaboration (UKCRC) Clinical Trials Units (CTUs) are increasingly exploring the use of digital tools to identify, recruit and retain participants. The aim of this UK National Institute for Health Research (NIHR) study was to identify what digital tools are currently used by CTUs and understand the performance characteristics required to be judged useful. Methods A scoping of searches (and a survey with NIHR funding staff), a survey with all 52 UKCRC CTUs and 16 qualitative interviews were conducted with five stakeholder groups including trialists within CTUs, funders and research participants. A purposive sampling approach was used to conduct the qualitative interviews during March-June 2018. Qualitative data were analysed using a content analysis and inductive approach. Results Responses from 24 (46%) CTUs identified that database-screening tools were the most widely used digital tool for recruitment, with the majority being considered effective. The reason (and to whom) these tools were considered effective was in identifying potential participants (for both Site staff and CTU staff) and reaching recruitment target (for CTU staff/CI). Fewer retention tools were used, with short message service (SMS) or email reminders to participants being the most reported. The qualitative interviews revealed five themes across all groups: 'security and transparency'; 'inclusivity and engagement'; 'human interaction'; 'obstacles and risks'; and 'potential benefits'. There was a high level of stakeholder acceptance of the use of digital tools to support trials, despite the lack of evidence to support them over more traditional techniques. Certain differences and similarities between stakeholder groups demonstrated the complexity and challenges of using digital tools for recruiting and retaining research participants. Conclusions Our studies identified a range of digital tools in use in recruitment and retention of RCTs, despite the lack of high-quality evidence to support their use. Understanding the type of digital tools in use to support recruitment and retention will help to inform funders and the wider research community about their value and relevance for future RCTs. Consideration of further focused digital tool reviews and primary research will help to reduce gaps in the evidence base.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pediatrics

Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial

Matthew J. Ridd, Miriam Santer, Stephanie J. MacNeill, Emily Sanderson, Sian Wells, Douglas Webb, Jonathan Banks, Eileen Sutton, Amanda Roberts, Lyn Liddiard, Zoe Wilkins, Julie Clayton, Kirsty Garfield, Tiffany J. Barrett, J. Athene Lane, Helen Baxter, Laura Howells, Jodi Taylor, Alastair D. Hay, Hywel C. Williams, Kim S. Thomas

Summary: This study compared the clinical effectiveness and safety of four main types of emollients (lotions, creams, gels, and ointments) commonly used for childhood eczema. The results showed no difference in eczema severity between the different types of emollients over a 16-week period. Users need to be able to choose an emollient that they are more likely to use effectively.

LANCET CHILD & ADOLESCENT HEALTH (2022)

Article Urology & Nephrology

Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial

Simon J. Crabb, Gareth Griffiths, Denise Dunkley, Nichola Downs, Mary Ellis, Mike Radford, Michelle Light, Josh Northey, Amy Whitehead, Sam Wilding, Alison J. Birtle, Vincent Khoo, Robert J. Jones

Summary: The addition of capivasertib to docetaxel may extend overall survival in patients with metastatic castration-resistant prostate cancer. Subgroup analysis suggests that the benefit is maintained in patients previously treated with androgen receptor-targeted agents.

EUROPEAN UROLOGY (2022)

Article Medicine, Research & Experimental

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment

L. Clark, B. Fitzgerald, S. Noble, S. MacNeill, S. Paramasivan, N. Cotterill, H. Hashim, S. Jha, P. Toozs-Hobson, T. Greenwell, N. Thiruchelvam, W. Agur, A. White, V. Garner, M. Cobos-Arrivabene, C. Clement, M. Cochrane, Y. Liu, A. L. Lewis, J. Taylor, J. A. Lane, M. J. Drake, C. Pope

Summary: This study aims to compare the effectiveness of surgical treatment and endoscopic bulking injections in women with recurrent or persistent SUI. The primary outcome is symptom severity measured using the ICIQ-UI-SF questionnaire, and secondary outcomes include longer-term clinical impact, symptom improvement, safety, operative assessments, sexual function, cost-effectiveness, and evaluation of patient and clinician perspectives. This research is important for guiding further treatment and improving symptoms and quality of life for women with this condition.

TRIALS (2022)

Article Oncology

ELEVATE - evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial

Elizabeth Smyth, Kelly Cozens, Daniel Griffiths, Kathryn L. Clark, Sean Ewings, Russell Petty, Tim Underwood, Rebecca C. Fitzgerald, James Tanner, Olivier Giger, Shubha Anand, Gareth Griffiths

Summary: This study aims to investigate the safety and biological effectiveness of administering Nivolumab after temozolomide treatment in patients with previously treated advanced oesophagogastric adenocarcinoma.

BMC CANCER (2022)

Article Dermatology

'Eczema shouldn't control you; you should control eczema': qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema

Kate Greenwell, Katy Sivyer, Laura Howells, Mary Steele, Matthew J. Ridd, Amanda Roberts, Amina Ahmed, Sandra Lawton, Sinead M. Langan, Julie Hooper, Sylvia Wilczynska, Paul Leighton, Gareth Griffiths, Tracey Sach, Paul Little, Hywel C. Williams, Kim S. Thomas, Lucy Yardley, Miriam Santer, Ingrid Muller

Summary: This study aimed to explore the views and experiences of individuals who have used the Eczema Care Online interventions, in order to understand their effectiveness and identify influencing factors. The findings suggest that the interventions are easy to use and trustworthy, and can help individuals manage their eczema by improving their understanding and confidence in eczema management, reducing treatment concerns, and enhancing treatment adherence and management of irritants/triggers.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Oncology

Variations in Penile Cancer Management: Results From the Global Society of Rare Genitourinary Tumors Survey

Gagan Prakash, Amandeep Arora, Marco Bandini, Giuseppe Basile, Mahendra Pal, Gareth Griffiths, Robert Cornes, Yao Zhu, Alejandro Rodriguez, Maarten Alberson, Andrea Necchi, Viraj Master, Curtis A. Pettaway, Philippe E. Spiess

Summary: Given the rarity of penile cancer, the Global Society of Rare Genitourinary Tumors (GSRGT) conducted a survey to identify the global variations in disease presentation and various aspects of its management. The results of this survey help identify research areas for multinational collaborative efforts which is a key mission of the GSRGT.

CLINICAL GENITOURINARY CANCER (2023)

Article Medicine, General & Internal

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

F. C. C. Hamdy, J. L. L. Donovan, J. A. Lane, C. Metcalfe, M. Davis, E. L. L. Turner, R. M. M. Martin, G. J. J. Young, E. I. I. Walsh, R. J. J. Bryant, P. Bollina, A. Doble, A. Doherty, D. Gillatt, V Gnanapragasam, O. Hughes, R. Kockelbergh, H. Kynaston, A. Paul, E. Paez, P. Powell, D. J. J. Rosario, E. Rowe, M. Mason, J. W. F. Catto, T. J. J. Peters, J. Oxley, N. J. J. Williams, J. Staffurth, D. E. E. Neal

Summary: A study in the UK showed that after 15 years of follow-up, the mortality rate of prostate cancer was low regardless of the treatment assigned. Therefore, the choice of therapy for localized prostate cancer involves considering the trade-offs between benefits and harms.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Medicine, General & Internal

Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial

Miriam Santer, Megan Lawrence, Susanne Renz, Zina Eminton, Beth Stuart, Tracey H. Sach, Sarah Pyne, Matthew J. Ridd, Nick Francis, Irene Soulsby, Karen Thomas, Natalia Permyakova, Paul Little, Ingrid Muller, Jacqui Nuttall, Gareth Griffiths, Kim S. Thomas, Alison M. Layton

Summary: This study assessed the effectiveness of oral spironolactone for acne vulgaris in adult women. The results showed that spironolactone had significant improvement in acne symptoms and quality of life compared to placebo at 12 weeks and 24 weeks, with no serious adverse reactions reported. This suggests that spironolactone is a useful alternative to oral antibiotics for women with acne.

BMJ-BRITISH MEDICAL JOURNAL (2023)

Article Oncology

Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial

Simon Crabb, Robin Wickens, Sarah Jane-Bibby, Denise Dunkley, Megan Lawrence, Allen Knight, Robert Jones, Alison Birtle, Robert Huddart, Mark Linch, Jonathan Martin, Adam Coleman, Konstantinos Boukas, Hannah Markham, Gareth Griffiths

Summary: This study aims to evaluate the safety and efficacy of PD-L1 directed immunotherapy atezolizumab in UTSCC patients. Preliminary translational data suggests potential therapeutic value. Through this study, we hope to provide a new treatment option for UTSCC patients.

BMC CANCER (2023)

Article Medicine, Research & Experimental

A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2)

Simon Crabb, Alannah Morgan, Myra S. S. Hunter, Evgenia Stefanopoulou, Gareth Griffiths, Alison Richardson, Deborah Fenlon, Louisa Fleure, James Raftery, Cherish Boxall, Sam Wilding, Jacqueline Nuttall, Zina Eminton, Emma Tilt, Alice O'Neill, Roger Bacon, Jonathan Martin

Summary: This study aims to assess the effectiveness of a guided self-help cognitive behavioural therapy (CBT) intervention, delivered by the existing NHS prostate cancer CNS team, in reducing the impact of hot flushes and night sweats (HFNS) in men undergoing androgen deprivation therapy (ADT). It will evaluate the intervention through a randomized controlled trial and explore the key influencers to its implementation through a process evaluation.

TRIALS (2023)

Article Pharmacology & Pharmacy

Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial

Merlin L. Willcox, Xiao-Yang Hu, Tom Oliver, Kerensa Thorne, Cherish Boxall, George He, Catherine Simpson, Becci Brotherwood, Alice O'Neil, Robert Waugh, Emma Tilt, Jeanne Trill, Neville Goward, Nick Francis, Michael Thomas, Paul Little, Tom Wilkinson, Jian-Ping Liu, Gareth Griffiths, Michael Moore

Summary: This study aimed to assess the feasibility of conducting a randomised placebo-controlled clinical trial of the Chinese herbal medicine Shufeng Jiedu (SFJD) for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in UK primary care. The results showed that the recruitment rate was lower than expected, possibly due to the lower incidence of AECOPD during the COVID-19 pandemic, patients starting antibiotics from rescue packs before seeing their GP, and challenges in the primary care workforce. However, the study was still able to demonstrate the feasibility of recruiting and randomising participants and identified approaches to address recruitment challenges.

FRONTIERS IN PHARMACOLOGY (2023)

Article Gastroenterology & Hepatology

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

John Reynolds, Shaun R. Preston, Brian O'Neill, Maeve A. Lowery, Lene Baeksgaard, Thomas Crosby, Moya Cunningham, Sinead Cuffe, Gareth Griffiths, Imelda Parker, Signe Lenora Risumlund, Rajarshi Roy, Stephen Falk, George B. Hanna, Frederick R. Bartlett, Alberto Alvarez-Iglesias, Michael P. Achiam, Magnus Nilsson, Guillaume Piessen, Narayanasamy Ravi, Dermot O'Toole, Ciaran Johnston, Raymond S. Mcdermott, Richard C. Turkington, Shajahan Wahed, Sharmila Sothi, Hugo Ford, Martin S. Wadley, Derek Power

Summary: The study compares trimodality therapy and perioperative chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction, showing similar 3-year survival rates and outcomes in terms of surgery and quality of life.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Article Respiratory System

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

Tom Wilkinson, Anthony De Soyza, Miles Carroll, James D. Chalmers, Michael G. Crooks, Gareth Griffiths, Manu Shankar-Hari, Ling-Pei Ho, Alex Horsley, Chris Kell, Beatriz Lara, Biswa Mishra, Rachel Moate, Clive Page, Hitesh Pandya, Jason Raw, Fred Reid, Dinesh Saralaya, Ian C. Scott, Salman Siddiqui, Andy Ustianowski, Natalie van Zuydam, Ashley Woodcock, Dave Singh

Summary: This study investigated the efficacy and safety of the anti-IL-33 monoclonal antibody tozorakimab in COVID-19 patients. The results suggest that tozorakimab could be a novel therapy for hospitalized COVID-19 patients.

ERJ OPEN RESEARCH (2023)

Article Medicine, General & Internal

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

Somnath Mukherjee, Christopher N. Hurt, Richard Adams, Andrew Bateman, Kevin M. Bradley, Sarah Bridges, Stephen Falk, Gareth Grif, Sarah Gwynne, Christopher M. Jones, PhilipJ. Markham, Tim Maughan, Lisette S. Nixon, Ganesh Radhakrishna, Rajarshi Roy, Simon Schoenbuchner, Hamid Sheikh, Emiliano Spezi, Maria Hawkins, Thomas D. L. Crosby

Summary: This study evaluated the role of F-18-Fluorodeoxyglucose positron emission tomography in assessing treatment response in patients with oesophageal cancer. The results showed that early metabolic response assessment after induction chemotherapy is not prognostic for treatment failure-free survival or overall survival, and should not be used to personalize systemic therapy selection.

ECLINICALMEDICINE (2023)

Article Medicine, General & Internal

Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial

Miriam Santer, Megan Lawrence, Susanne Renz, Zina Eminton, Beth Stuart, Tracey H. Sach, Sarah Pyne, Matthew J. Ridd, Nick Francis, Irene Soulsby, Karen Thomas, Natalia Permyakova, Paul Little, Ingrid Muller, Jacqui Nuttall, Gareth Griffiths, Kim S. Thomas, Alison M. Layton

Summary: Oral spironolactone is effective in improving symptoms and quality of life for adult women with acne vulgaris, with better efficacy compared to oral antibiotics.

BMJ-BRITISH MEDICAL JOURNAL (2023)

No Data Available